A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists

Abstract

Background and purpose Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short‐ or long‐acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. Methods A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short‐ and long‐acting, and transdermal) across a broad range of disease stages and age groups was performed. Results Four hundred and twenty‐five cases were included [mean age 68.3 years (range 37–90), mean duration of disease 7.5 years (range 0–37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P < 0.05) compared with any other assessed DAs except for prolonged release PPX (PPX‐PR). The rate of ICDs for PPX‐PR (6.6%) was significantly lower than for immediate release PPX (PPX‐IR) (19.0%; P < 0.05). Discontinuation rates of DA therapy due to ICDs were low. Conclusion Our data suggest a relatively low rate of ICDs with long‐acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.

A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps

“…However, the greatest risk factor for triggering these addictive behaviors is DA therapy . Immediate release orally active agonists appear to carry increased risk for ICBs when compared to transdermal or prolonged release oral agonists …”

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

“…Although rotigotine has been reported to confer a lower risk compared with other DAs (Garcia‐Ruiz et al., 2014; Moore, Khalaj, et al., 2014; Rizos et al., 2016), rotigotine has D3 receptor affinity, and furthermore, in a post hoc analysis of six open‐label extension studies, 71 of 786 patients (9%) with rotigotine treatment developed ICB (Antonini et al., 2016). Hence, rotigotine could be a risk factor for the development of ICB.…”

Untitled

“…En 2013 se reportó en la revista Brain que el uso de piribedil (un agonista D2-D3) aliviaba 67 el cual determinó la asociación de trastornos de control de impulsos con el uso de agonistas de acción corta y acción prolongada. En este estudio se recabaron datos de distintos centros europeos que señalaron una menor tasa de trastornos del control de impulsos en los pacientes que utilizaban rotigotina transdérmica o agonistas de acción prolongada.…”